^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)

i
Other names: PABPC1L, Poly(A) Binding Protein Cytoplasmic 1 Like, DJ1069P2.3, C20orf119, PABPC1L1, EPAB, Polyadenylate-Binding Protein 1-Like, Poly(A) Binding Protein, Cytoplasmic 1-Like, Chromosome 20 Open Reading Frame 119, Embryonic Poly(A) Binding Protein
Associations
Trials
3ms
Coordinated upregulation of PABPC1L and SNHG lncRNAs defines a tumor-specific expression module in colorectal cancer: evidence from paired tumor-normal expression profiling. (PubMed, Biochem Biophys Rep)
The combined four-gene model demonstrated moderate discriminatory power, yielding an AUC of 0.76 (95 % CI 0.65-0.86, p < 0.0001) with balanced sensitivity and specificity of 69.8 % each at the 0.5 cutoff (overall accuracy 69.8 %). Taken together, RUSC1-AS1, SNHG17, PABPC1L and SNHG1 can be novel candidates for future diagnostic studies in CRC.
Journal
|
SNHG1 (Small Nucleolar RNA Host Gene 1) • PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like) • SNHG17 (Small Nucleolar RNA Host Gene 17) • RUSC1-AS1 (RUSC1 Antisense RNA 1)
9ms
Identification and validation of a 9-RBPs-related gene signature associated with prognosis and immune infiltration in bladder cancer based on bioinformatics analysis and machine learning. (PubMed, Transl Androl Urol)
This study successfully identified and developed a prognostic signature based on nine RBPs, accompanied by a nomogram for predicting survival probability in BLCA patients. Our findings demonstrate that these nine RBPs function as significant biomarkers for forecasting the prognosis and immune status in BLCA, suggesting their potential as therapeutic targets for BLCA.
Journal • Gene Signature
|
IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)
almost2years
A novel risk signature based on liquid-liquid phase separation-related genes reveals prognostic and tumour microenvironmental features in clear cell renal cell carcinoma. (PubMed, Aging (Albany NY))
We developed a risk signature constructed based on the five LLPS-related genes and can have a high ability to predict the prognosis of ccRCC patients, further providing a strong support for clinical decision-making.
Journal
|
PLK1 (Polo Like Kinase 1) • PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)
2years
PABPC1L induces IDO1 to promote tryptophan metabolism and immune suppression in renal cell carcinoma. (PubMed, Cancer Res)
Conversely, loss of PABPC1L diminished IDO1 expression, mitigated cytotoxic T-cell suppression, and enhanced responsiveness to anti-PD-1 therapy in patient-derived xenograft models. These findings reveal the crucial role of PABPC1L in facilitating immune evasion in RCC and indicate that inhibiting PABPC1L could be a potential immunotherapeutic approach in combination with ICB to improve patient outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
IDO1 (Indoleamine 2,3-dioxygenase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)
|
IDO1 expression
2years
Visium spatial transcriptomics reveals intratumor heterogeneity and profiles of Gleason score progression in prostate cancer. (PubMed, iScience)
Enrichment analysis showed that biological functions, such as cadherin binding, Golgi vesicle transport, protein folding, and cell adhesion molecules were related to GS progression. In conclusion, this study provides insight into ST-based transcriptome-wide expression patterns during GS progression.
Journal
|
PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)
almost3years
Comprehensive genomics analysis of aging related gene signature to predict the prognosis and drug resistance of colon adenocarcinoma. (PubMed, Front Pharmacol)
Low risk patients were more sensitive to small molecule drugs including Erlotinib, Sunitinib, MG-132, CGP-082996, AZ628, Sorafenib, VX-680, and Z-LLNle-CHO. Four risk genes (CALB1, CPA3, NOXA1, and TNNT1) had significant positive correlation with their methylation level, while six genes (CCL22, GPRC5B, HSPA1A, MFNG, PABPC1L, and PCOLCE2) were negatively correlated with their methylation level. This study provides novel understanding of heterogeneity in COAD from the perspective of senescence, and develops signatures for prognosis prediction in COAD.
Journal • Tumor mutational burden • Gene Signature • IO biomarker
|
TMB (Tumor Mutational Burden) • CCL2 (Chemokine (C-C motif) ligand 2) • CALB1 (Calbindin 1) • CCL22 (C-C Motif Chemokine Ligand 22) • CPA3 (Carboxypeptidase A3) • HSPA1A (Heat Shock Protein Family A (Hsp70) Member 1A) • PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like)
|
erlotinib • sorafenib • sunitinib • AZ 628 • MG132 • tozasertib (MK-0457)